Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users

Inclusion Criteria: * Continuous treatment (at least once daily) with BZD/Z for at least 6 months, after verification of 6 months' supply. * Signed informed consent * Patient able to understand the survey and complete a questionnaire in French. * Affiliation with the French social security system Exclusion Criteria: * Concomitant treatment with: * The following oral antipsychotics: risperidone, olanzapine, aripiprazole, quetiapine, clozapine, haloperidol, flupentixol, pimozide, chlorpromazine, sulpiride, zuclopenthixol, loxapine, cyamemazine (\>100mg/D), sulpiride (\>150mg/D), * Injectable medium- and long-acting antipsychotics * Thymoregulatory treatment with lithium * Treatments for alcohol use disorders: baclofen, nalmefene, naltrexone, acamprosate, disulfiram * Opiate substitution treatments: buprenorphine, methadone * Anti-epileptic drugs * History of convulsions or epilepsy * History of gabaergic withdrawal accidents: delirium tremens, confusional syndrome requiring specialist treatment (hospitalisation, specialist consultation), epileptic seizures, etc. * Patients suffering from cancer * Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons: pregnant women, women in childbirth, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure).